INO241101C5000
- 0.77
- 0.000.00%
Inovio Pharmaceuticals Newsroom
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Inovio Pharmaceuticals Analyst Ratings
RBC Cuts Price Target on Inovio Pharmaceuticals to $7 From $8, Keeps Sector Perform, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS) and Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals (INO) Receives a Buy From Oppenheimer
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals: Hold Rating Amidst Financial Concerns and INO-3107 Development Delays
RBC Cuts Price Target on Inovio Pharmaceuticals to $8 From $11, Keeps Sector Perform, Speculative Risk
Inovio Pharmaceuticals: Maintaining Buy Rating Amid BLA Submission Delay
Analysts Conflicted on These Healthcare Names: Daiichi Sankyo Company (OtherDSKYF), Inovio Pharmaceuticals (INO) and Molina Healthcare (MOH)
Inovio Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $15 Price Target
Inovio Pharmaceuticals Receives 'Buy' Rating Amidst UK Regulatory Advancements and Promising RRP Treatment Outlook
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals: Hold Rating Amidst Clinical Progress and Financial Caution
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals: Hold Rating With Promising Pipeline Despite Financial Losses
RBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)